Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.

Clinical and translational science - 1 May 2025

Luzum Jasmine A, Littleton Shana D R, Lopez-Medina Ana I, Liu Bin, She Ruicong, Lanfear David E

Abstract excerpt

Previous pharmacogenetic findings for beta-blocker pharmacodynamic candidate genes (ADRB1, ADRB2, ADRA2C, GRK4, and GRK5) have been inconsistent. Therefore, the purpose of this study was to determine whether interactions of pharmacodynamic variants with beta-blocker exposure significantly associated with survival in patients with heart failure with reduced ejection (HFrEF). The 893 patients were 51% self-reported...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Black or African American

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Heart Failure

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Receptors, Adrenergic, beta-1

Source

Open in PubMed Open full text

Identifiers

PMID: 40285373
DOI: 10.1111/cts.70239
PMCID: PMC12031879

Genes

ADRB1
GRK4
ADRA2C
ADRB2
GRK5

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Beta-Blocker Pharmacogenetic Puzzle: More Pieces of Evidence for Pharmacodynamic Candidate Variants.PMID 40285373Read ↗

Clinical and genetic modifiers of long-term survival in heart failure.Semantic proximity Read ↗

Pharmacogenomics of heart failure.Semantic proximity Read ↗

Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heart-failure patients.Semantic proximity Read ↗

Genetic polymorphisms in ADRB2 and ADRB1 are associated with differential survival in heart failure patients taking β-blockers.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

Pharmacogenetic factors affecting β-blocker metabolism and response.Semantic proximity Read ↗

A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure.Semantic proximity Read ↗

β-adrenergic receptor polymorphisms in susceptibility, response to treatment and prognosis in heart failure: implication of ethnicity.Semantic proximity Read ↗

Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.Semantic proximity Read ↗

Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read ↗

Effects of GRK5 and ADRB1 polymorphisms influence on systolic heart failure.Semantic proximity Read ↗

Effect of specific ADRB1/ADRB2/AGT genotype combinations on the association between survival and carvedilol treatment in chronic heart failure: a substudy of the ECHOS trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.